New Medicines Listed on PBS

By Petrina Smith
Wednesday, 18 December, 2013

Medicines to treat diabetes and lung cancer have been added to the Pharmaceutical Benefits Scheme (PBS).
The PBS listing of the new medicines or combinations of medicines will apply from 1 February 2014, making these therapies considerably cheaper for Australian patients.
For patients with diabetes, a combination dose of aloglitpin with metformin (sold as Nesina Met®) has now been listed. While the drugs were already listed individually, many patients need to use both medicines at once to treat their condition.
“Making this combination dose available through the PBS will save many patients up to $36.90 whenever they get a script filled because they will be able to buy one medicine instead of two,” the Minister for Health, Peter Dutton said.
“More than 50,000 people are expected to obtain the combined medicine through the PBS over the next five years. With an average of seven packs each over that period, this represents a considerable saving to people living with diabetes.”
Mr Dutton also announced the PBS listing of erlotinib (sold as Tarceva®) for the treatment of non-small cell lung cancer. The listing provides another treatment option for this type of cancer, following approval in November of PBS listing for gefitinib (sold as Iressa®).
“About 1400 Australian patients with non-small cell lung cancer will now have a choice of subsidised treatment options for this serious disease,” Mr Dutton said.
All PBS listings are subject to final arrangements being met by the suppliers of the medicine.
Mr Dutton also announced that a number of existing PBS drugs would be cheaper to both the Australian Government and health consumers from 1 April 2014.
Common medicines which will be cheaper to consumers from 1 April, as a result of price disclosure, include:

  • Rabreprazole for gastric reflux, up to $8.78 cheaper per script, saving consumers around $7 million a year

  • Escitalopram for depression, up to $3.43 cheaper per script, saving non-concessional patients around $5.6 million a year

  • Simvastatin for high cholesterol, up to $5.18 cheaper per script, saving patients around $2.6 million a year.

Three of the top five price reductions from 1 April will apply to cancer medicines.
“These price cuts are the result of price disclosure which was initially introduced in 2007 as part of the Howard Government’s PBS reforms,” Mr Dutton said.
“This means that the Government pays a fairer price for the medicines it subsidises. The resulting savings are being used to extend subsidies to new and innovative drugs to treat Australian patients.”
Related News

Tool helps cancer survivors manage post-treatment uncertainty

UNSW researchers are using e-health to investigate ways to help cancer survivors access treatment...

Need to cut through alcohol and breastfeeding misinformation

Two-thirds of Australian women who breastfeed feel they do not fully understood the risks of...

Study explores techniques for reducing needle anxiety

A University of South Australia study has found two new nurse-led techniques that help reduce...

  • All content Copyright © 2022 Westwick-Farrow Pty Ltd